Lv67
2840 积分 2023-07-31 加入
Physiologically Based Pharmacokinetic Modeling of Midostaurin and Metabolites at Steady-state to Bridge Drug Interaction Scenarios In Lieu of Clinical Trials
11天前
已关闭
Model‐Based Investigation of Inadequate Efficacy of Tesnatilimab, an Anti–Natural Killer Group 2 Member D Monoclonal Antibody, in Moderately to Severely Active Crohn Disease
20天前
已完结
Model‐Based Investigation of Inadequate Efficacy of Tesnatilimab, an Anti–Natural Killer Group 2 Member D Monoclonal Antibody, in Moderately to Severely Active Crohn Disease
29天前
已完结
Blocking common γ chain cytokine signaling ameliorates T cell–mediated pathogenesis in disease models
30天前
已完结
Optimal design in pediatric pharmacokinetic and pharmacodynamic clinical studies
1个月前
已完结
Prospective Evaluation of a D-Optimal Designed Population Pharmacokinetic Study
1个月前
已完结
An Evaluation of an Optimal Sampling Strategy for Meropenem in Febrile Neutropenics
1个月前
已完结
Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs
1个月前
已完结
Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice
1个月前
已完结
Physiologically Based Pharmacokinetic Model of the DPP-4 Inhibitor Linagliptin to Describe its Nonlinear Pharmacokinetics in Humans
9个月前
已完结
皖公网安备34019202002308
